SEIMC-GeSIDA Foundation and ViiV Healthcare announced positive 48-week results from the Paso Doble study (GeSIDA study 11720), the largest randomized…
Gilead presented results from the third phase of the Purpose 1 clinical trial, which assessed the effectiveness of a six-month…
“PrEP represents an important milestone in HIV prevention and gives us the opportunity to significantly reduce the scale of a…